Zoom has announced that it will be going public on April 18th 2019. This has generated substantial hype and lead to a valuation of $36 per share tomorrow. In this article I will discuss; Potential … [Read more...] about Should You Buy The ZOOM IPO?
stocks
An Intro to EMA’s When Trading Biotech Stocks
https://www.youtube.com/watch?v=4MecjQHamEo&ab_channel=M%26SMoneyMoves … [Read more...] about An Intro to EMA’s When Trading Biotech Stocks
MS Identified Its Next Swing
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. Preface WOW. We are absolutely elated with the performance of our last swing move on SCYX. In case you missed it on … [Read more...] about MS Identified Its Next Swing
A Closer Look At CNAT’s “Failed” Clinical Study
Introduction Conatus Pharmaceuticals (Nasdaq: CNAT) recently released highly anticipated top-line data from their Encore-PH clinical trial. The study investigated the efficacy and safety of … [Read more...] about A Closer Look At CNAT’s “Failed” Clinical Study
Ørsted Positioning For A Foothold In U.S. Markets
Ørsted is the leading the market in the UK.Ørsted set out to be an entirely green company 10 years ago.After dominating the UK market, Ørsted is turning to the opportunities in the U.S.Ørsted intends … [Read more...] about Ørsted Positioning For A Foothold In U.S. Markets
Moving Averages; SMA & EMA Explained
Overview We have recently begun releasing educational pieces on technical strategies. The most recent article covering RSI got us thinking about other useful indicators for the less seasoned … [Read more...] about Moving Averages; SMA & EMA Explained
Shorts Fighting To Keep CPRX from Gaining Momentum-Insiders Aren’t Phased
After a little research it appears that shorts are working overtime to hold Catalyst Pharmaceuticals (Nasdaq: CPRX) under $3.0. Only 5 days ago we were at $3.20. A month ago and before the PDUFA date … [Read more...] about Shorts Fighting To Keep CPRX from Gaining Momentum-Insiders Aren’t Phased
Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Investing at A Young Age: How My First Two Stock Investments Tripled
By MS Author: Zane Foley “Invest in Apple, invest in Tesla,” these were the stocks people, parents and professors were telling me to invest in after working my first salary position after college; but … [Read more...] about Investing at A Young Age: How My First Two Stock Investments Tripled
Galectin Blocker is Front Runner in Fight Against NASH-Cirrhosis
GALT’s phase 3 study inclusion criteria will be patients diagnosed with NASH-cirrhosis but without varices, and includes an interim analysis. Competition in the NASH-cirrhosis space is lacking. The … [Read more...] about Galectin Blocker is Front Runner in Fight Against NASH-Cirrhosis
